Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: A case-based review

Clinical Lung Cancer

Volumn 12, Issue 4, 2011, Pages 212-217

  Adjei, Alex ^a   Blumenschein Jr , George ^b   Mandrekar, Sumithra ^c   Hillman, Shauna ^c   Gatzemeier, Ulrich ^d   Heigener, David ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MAYO CLINIC   (United States)

^d KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Anti angiognesis; Epidermal growth factor receptor; Gefitinib; Multikinase inhibitor; Toxicity; Tyrosine kinase

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; SORAFENIB;

ADVANCED CANCER; ALOPECIA; ANOREXIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; PARESTHESIA; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; SKIN PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79960343099     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.021     Document Type: Article

References (35)

1. American Cancer Society. Cancer Facts & Figures 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed May 26, 2010.
2. Parkin DM, Bray F, FerlayJ, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. American Cancer Society. Detailed Guide: Lung Cancer-Non-Small Cell. How Is Non-Small Cell Lung Cancer Staged? Available at: http://www.cancer.org/ docroot/CRI/content/CRI-2-4-3x-How-Is-NonSmall-Cell-Lung-Cancer-Staged.asp?rnav= cri. Accessed May 26, 2010.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer V.2.2010. Available at: http://www.nc-cn.org/professionals/physician-gls/PDF/nscl.pdf. Accessed May 26, 2010.
5. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. JClin Oncol2004; 22:330-53. (Pubitemid 41095099)
6. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13:2684-91. (Pubitemid 46788036)
7. Cho BC, Im K-C, Park M-S, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25:2528-33. (Pubitemid 47041225)
8. Nakatomi K, Soda H, Kitazaki T, et al. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 2006; 52:253-5.
9. Reck M, Gatzemeier U. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. Lung Cancer 2005; 50:107-14. (Pubitemid 41297477)
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39. (Pubitemid 38637993)
11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500. (Pubitemid 38720929)
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11. (Pubitemid 39209661)
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci-zumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
14. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-50. (Pubitemid 350086476)
15. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227-34.
16. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21:1804-9.
17. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a mul-tikinase inhibitor that targets both Raf and VEGF and PDGF receptor signaling. Mol Cancer Ther 2008; 7:3129-40.
18. European Medicines Agency. Nexavar Summary of Product Characteristics. 2006. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/emea- combined-h690en.pdf. Accessed May 26, 2010.
19. Nexavar (sorafenib) tablets [prescription information]: Wayne, NJ. Bayer HealthCare Pharmaceuticals; 2009. Available at: http://berlex.bayerhealthcare. com/html/products/pi/Nexavar-PI.pdf. Accessed May 26, 2010.
20. Dy GK, Hillman SL, Rowland KM Jr, et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. North Central Cancer Treatment Group Study N0326. Cancer 2010; 116: 5686-93.
21. Duran I, Hotte SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007; 13:4849-57. (Pubitemid 47294792)
22. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007; 13:1801-9. (Pubitemid 46952949)
23. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:4274-80.
24. Liu B, Barrett T, Choyke P, et al. A Phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(Suppl):676S Abstract 17119.
25. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34. (Pubitemid 46089673)
26. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
27. Cheng A-L, Kang TK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
28. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:1835-42.
29. Schiller J, Lee J-W, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501. International Association for the Study of Lung Cancer 13th World Conference on Lung Cancer. San Francisco, CA: July 31-August 4, 2009 Abstract C1.6.
30. Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006; 7:241-9. (Pubitemid 43280026)
31. Flaherty KT, Brose MS. Sorafenib-related hand-foot skin reaction improves, not worsens, with continued treatment. Clin Cancer Res 2009; 15:7749.
32. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372:1809-18.
33. Wood LS, Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs 2007; 11:649-56.
34. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007; 30:519-24. (Pubitemid 47462063)
35. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 2008; 13(Suppl 1):37-46.